Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
https://doi.org/10.18008/1816-5095-2025-1-92-99
Abstract
Relevance. Angiogenesis inhibitors in the treatment of age-related macular degeneration (AMD) do not eliminate the oxidative stress associated with this pathology.
Purpose: evaluation of complex therapy for neovascular AMD (nAMD) combining the nutraceutical Resvera Forte® (VISUS LAB LLC) with intravitreal administration of aflibercept.
Patients and methods. The study involved 36 patients (36 eyes) with nAMD, aged 72.0 ± 3.8 years. Two groups were formed, comparable by gender and age. In the main group (20 patients), in addition to aflibercept therapy, an oral course of the multivitamin complex Resvera Forte® (712 mg) was prescribed. In the comparison group (16 patients, 16 eyes), aflibercept therapy was administered. The observation period was 1.5 years.
Results. After three “loading” intravitreal injections of aflibercept, all 36 patients showed a decrease in macular neovascularization activity, the interval was increased by 2 weeks. By 12 months, no patient in the main group had AMD activity, the central retinal thickness (CRT) decreased to 251.5±9.1 μm, and the best-corrected visual acuity (BCVA) increased to 0.8 ± 0.06. The average number of intravitreal injections per year in the main group was 7 ± 1. In the comparison group, six patients showed resumption of AMD activity, which required an increase in the number of injections to 9–10 per year. CRT was 293.0 ± 20.3 μm versus 251.5 ± 9.1 μm in the main group (p < 0.08). The BCVA in the comparison group was 0.8 ± 0.06 versus 0.6 ± 0.09 in the main group (p < 0.05).
Conclusion. Supplementation of anti-VEGF therapy for nAMD with the oral nutraceutical Resvera Forte® contributed to an objective improvement in the morphofunctional results of its treatment.
About the Authors
L. A. Golota
The Khabarovsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Golota Lyudmila A., ophthalmologist of the Vitreoretinal Surgery Department no. 2
Tikhookeanskaya str., 211, Khabarovsk, 680033
N. V. Pomytkina
The Khabarovsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution; Far Eastern State Medical University
Russian Federation
Russian Federation
Pomytkina Natalia V., PhD., ophthalmologist of the Laser Surgery Department; assistant of the General and Clinical Surgery Department
Tikhookeanskaya str., 211, Khabarovsk, 680033
Murav’yeva-Amurskogo str., 35, Khabarovsk, 680000
L. P. Danilova
The Khabarovsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Danilova Lyubov P., Head of the Department of the Vitreoretinal Surgery Department no. 2,
ophthalmologist
Tikhookeanskaya str., 211, Khabarovsk, 680033
References
1. Thomas CJ, Mirza RG, Gill MK. Age-Related Macular Degeneration. Med Clin North Am. 2021;105(3):473–491. doi: 10.1016/j.mcna.2021.01.003.
2. Chang MA, Bresler SB, Munoz B., West SC Racial differences and other risk factors for the incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation Project (SEE). Investig. Ophthalmol. Vis. Sci. 2008;49:2395–2402. doi: 10.1167/iovs.07-1584.
3. Tereshchenko AV, Belyi YA, Kovalevskaya MA, Milyutkina SO. The evaluation attempts in anti-VEGF therapy of AMD macular edema. Fyodorov Journal of Ophthalmic Surgery. 2014;4:95‒100 (In Russ.).
4. Boiko EV, Churashov SV, Kamilova TA. Molecular genetic basis of age-related macular degeneration. Russian Annals of Ophthalmology. 2013;129(2):86–90 (In Russ.).
5. Eskina EN., Belogurova AV, Gvetadze AA, Smorchkova AS. Practical application of ophthalmic nutraceuticals in patients with dry form of age-related macular degeneration. Russian Annals of Ophthalmology. 2020;136(4):86–92 (In Russ.). doi: 10.17116/oftalma202013604186.
6. Egorov VV, Gokhua TI, Smolyakova GP, Danilova LP, Emanova LP, Zhaivoronok NS. Far Eastern natural phytomineral remedies in the treatment of eye diseases. Part I. Use of the Far Eastern natural phytomineral remedy Lamifaren in the treatment of age-related macular degeneration of the retina. RMJ. Clinical ophthalmology. 2012;13(2):74–77 (In Russ.).
7. Clinical guidelines. Age-related macular degeneration. All-Russian public organization “Association of ophthalmologists”; 2024 (In Russ.). URL: https:// diseases.medelement.com/disease/макулярная-дегенерация-возрастная-кррф-2024/18141 1 (аccessed 01/27/2025).
8. Danilova LP, Egorov VV, Smoliakova GP, Povalyaeva DА, Zhajvoronok NS, Udovichenko ЕV, Emanova LP. Effectiveness of combined therapy of neovascular agerelated macular degeneration using anti-VEGF drug aflibercept and nutraceutical “Resvega Forte”. Modern technologies in ophthalmology. 2021;(1):153–157 (In Russ.). doi: 10.25276/2312-4911-2021-1-153-157.
9. Egorov VV, Gokhua TI, Smoliakova GP, Danilova LP, Emanova LP, Zhaivoronok NS. Treatment of an age-related macular degeneration with application of the fareastern natural phyto-mineral complex-gel “LAMIFAREN”. Bulletin of the East Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences. 2011;6:29–31 (In Russ.).
10. Certificate of state registration of products No. AM.01.20.003.R.000656.12.24; TU 10.89.19-126-35002567-2024 (In Russ.).
11. VEGF Trap-Eye (aflibercept ophthalmic solution) briefing document. Ophthalmologic Drugs Advisory Committee. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2011.
12. State Register of Medicines. Instructions for medical use of the medicinal product Eylea LP003544 from 2020 (In Russ.).
13. Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89–99. doi: 10.1016/j.ophtha.2020.06.028.
14. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1.
15. Danilova LP, Egorov VV, Smolyakova GP, Emanova LP, Shvachko NS. Analysis of the efficacy of angiogenesis inhibitor ranibizumab in the treatment of choroidal neovascularization in patients with age-related macular degeneration. Public health of the Far East. 2010:2:35–38 (In Russ.).
16. Alghamdi A, Keegan D, Connell P, Dooley I, O’Toole L. Adherence of patients with age-related macular degeneration to AREDS 2-recommended nutritional supplements. Ir J Med Sci. 2023;192(6):3163–3167. doi: 10.1007/s11845-023-03351-4.
17. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA. 2006;103(7):2328–2333. doi: .1073/pnas.0408835103.
18. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA. 2006;103(44):16182–7. doi: 10.1073/pnas.0604255103.
Review
For citations:
Golota L.A., Pomytkina N.V., Danilova L.P. Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment. Ophthalmology in Russia. 2025;22(1):92-99. (In Russ.) https://doi.org/10.18008/1816-5095-2025-1-92-99
Views:
290
Email this article 